Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Non-Current Liabilities: 2017-2025

Historic Other Non-Current Liabilities for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $152.0 million.

  • Arcus Biosciences' Other Non-Current Liabilities rose 11.76% to $152.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.0 million, marking a year-over-year increase of 11.76%. This contributed to the annual value of $157.0 million for FY2024, which is 10.56% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Other Non-Current Liabilities is $152.0 million, which was down 4.40% from $159.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Other Non-Current Liabilities ranged from a high of $166.0 million in Q1 2025 and a low of $10.2 million during Q1 2021.
  • Its 3-year average for Other Non-Current Liabilities is $147.6 million, with a median of $145.0 million in 2023.
  • As far as peak fluctuations go, Arcus Biosciences' Other Non-Current Liabilities skyrocketed by 22,367.77% in 2021, and later decreased by 6.21% in 2024.
  • Arcus Biosciences' Other Non-Current Liabilities (Quarterly) stood at $122.0 million in 2021, then climbed by 14.75% to $140.0 million in 2022, then climbed by 1.43% to $142.0 million in 2023, then rose by 10.56% to $157.0 million in 2024, then climbed by 11.76% to $152.0 million in 2025.
  • Its Other Non-Current Liabilities was $152.0 million in Q3 2025, compared to $159.0 million in Q2 2025 and $166.0 million in Q1 2025.